DOI: https://doi.org/10.21203/rs.3.rs-151765/v1
Background: Adaptor protein complex-4 (AP-4), a heterotetrameric protein complex, plays an important role in vesicle trafficking in neurons. Mutations in genes affecting different subunits of AP-4, including AP4B1, AP4E1, AP4S1, and AP4M1, have been recently associated with spastic tetraplegia, developmental delay and intellectual disability (ID).
Case presentation: We report on a Chinese patient with infantile spasms, infantile hypotonia and global developmental delay. Exome sequencing showed compound heterozygous mutations in AP4M1(c.19A>G, p.I7V and c.137C>T, p.P46L).
Conclusions: This is the first case of biallelic missense variants lay on the region encoding LH domain, which is important for membrane trafficking via protein–protein and intramolecular binding specificities. Our study expands the molecular spectrum associated with AP-4 deficiency syndrome, and reviews the clinical features of reported patients with AP4M1 mutations.
The Adaptor related protein complex4(AP4M1) gene encodes a subunit of the heterotetrameric adaptor protein complex 4(AP4), which is composed of two large chains beta-4 (AP4B1) and epsilon-4 (AP4E1), a medium mu-4 chain (AP4M1) and a small sigma-4 chain (AP4S1)[1]. AP-4 complex-mediated trafficking plays a crucial role in brain development and function. AP-4 deficiency syndrome, also known as AP-4 associated hereditary spastic paraplegia (HSP), is a group of neurodegenerative disorders characterized by developmental delay, severe intellectual disability, spasticity and microcephaly of essentially postnatal onset. Early-onset hypotonia evolves into progressive lower-extremity spasticity[2,3]. Here we present a case of compound heterozygous AP4M1 mutations in a Chinese girl with infantile spasms, infantile hypotonia and global developmental delay, and review the clinical features of patients with AP4M1 mutations.
The infant was the first child born to the non-consanguineous Chinese parents (Figure1a), She was a full-term newborn by cesarean delivery with no perinatal brain injury, hypoxia, or infection the central nervous system. The parents declared no family history of epilepsy or other neurological conditions. Developmental delay was noticed when she was unable to track, hold up her head and sit independently at six months. She started to have infantile spasms when she was 7 months, with the symptom of clustered flexor spasm of upper limbs, eyes rolling and head nodding. Interictal EEG revealed hypsarrhythmia. The seizure frequency was up to 15 times per day. Multiple anti-epileptic drugs including sodium valproate, topamax and prednisone were given to the patient, but seizures were not well controlled with a frequency of about 10 times a day. Low-dose adrenocorticotropic hormone (ACTH) therapy was given combined with sodium valproate and topamax at the age of 8 months, but with no improvement of seizures control indicated by EEG after 14 days of treatment. We then replaced the ACTH with sabril and continued the treatment, the seizures were finally under control after three days. On the examination at 10 months, she could hold up her head and sit independently for a few minutes, hypotonia and limbs weakness were observed. Body height and head circumference were in normal range. Blood routine examination showed thrombocytopenia, which may relate to the use of several antiepileptic drugs.
Blood and urine screenings for genetic metabolic disorders were negative. Developmental Screen Test (DST) at 7 months showed the developmental quotient (DQ) was below 60 and the mental index (MI) was less than 46, scores less than 70 on DQ and MI are considered abnormal. Brain MRI of 3.0 Tesla at 7 months indicated delayed myelination and nonspecific loss of bilateral frontal-parietal lobes white matter (Figure1b). Interictal EEG at 7 months showed hypsarrhythmia consisting of bilateral high-amplitude irregular slow waves mixed with multiple focal spikes or poly spikes in the interictal period (Figure1c).
Whole-exome sequencing (WES) was performed in the proband and her parents. The proband’s Trio-WES identified compound heterozygous mutations in AP4M1(c.19A>G, p.I7V and c.137C>T, p.P46L) (Figure1a). The two missense variants are highly conserved (GERP++, phastCons46way primates) and located at the longin-like (LH) domain, and are predicted to be damaging by several prediction tools (SIFT, PolyPhen2, and Mutation Taster). Segregation analysis by Sanger sequencing confirmed that the compound heterozygous state of these variants is segregating with the phenotype (Figure2a).
AP complexes are crucial for vesicular trafficking from the trans-Golgi network to the plasma membrane[4,5]. Defects of either the B1, E1, M1 or S1 subunit of AP4 are characterized by the combination of infantile hypotonia, developmental delay, intellectual disability, early-onset spastic paraplegia, and thinning of the corpus callosum on brain MRI[6]. Autosomal recessive HSP due to pathogenic variants in AP4M1 is a rare neurodevelopmental disorder. Very few patients and families have been described in the literatures. To date, only 22 patients from ten families with pathogenic AP4M1 variants have been reported (figure2b)[7,8,2,9,6,1,10-12]. We summarized the clinical features of patients with AP4M1 mutations in table1. Among these pathogenic variants, most of these variants are positioned within a region encoding the mu homology domain (MHD), an essential protein-protein interaction module. Only the biallelic frameshift mutation lays on a position encoding LH domain located in the N-terminal part of the protein, causing premature stop codons and truncating the protein before MHD[10]. Truncation mediated decay of the entire mRNA, is likely to cause complete loss of AP4M1 function. Patients with biallelic loss-of-function mutations of AP4M1 have been described with severe infantile hypotonia and diffuse white matter loss on brain MRI[7-9,1]. It is speculated that the AP4M1 defect results in abnormal cycling of glutamate receptors, mimicking glutamate mediated perinatal white matter injury[7].
Here we report the compound heterozygous mutations in AP4M1(c. 19A>G and c.137C>T) on a patient with infantile spasms, infantile hypotonia and developmental delay. This is the first case of biallelic missense variants lay on the region encoding LH domain, which is important for membrane trafficking via protein–protein and intramolecular binding specificities. It was reported that the missense mutations generally result in a milder phenotype compared to the homozygous truncated mutations have been identified[1]. Due to a residual function of the AP4M1 gene, the affected individual in this study showed a milder presentation, with normal occipitofrontal circumference and no diffuse white matter involvement on her brain MRI. Phenotypic heterogeneity may be related to the different protein domains affected. Our study expands the molecular spectrum associated with AP-4 deficiency syndrome. Further studies are needed to investigate the role of AP-4 in brain development and neurotransmission.
AP4M1: Adaptor related protein complex4; EEG: Electroencephalogram; MRI: Magnetic resonance imaging; WES: Whole exome sequencing; DST: Developmental Screen Test; DQ: Developmental quotient;
Ethics approval and consent to participate
The study protocol was approved by the Ethic Committee of the Xiangya Hospital of Central South University. Written informed consent was obtained from the patients' father.
Consent for publication
Written informed consent for publication was obtained from the participants or their guardians.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by grants from the Natural Science Foundation of Hunan Province, China (grant number 2020JJ4854), Research project of Chenzhou first people's Hospital (grant number N2019-020). The funding body had no influence in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Authors’ contributions
XBJ and LLZ designed the study, monitored the family investigation, collected clinic data, drafted and revised the manuscript. YQW contributed to exome sequencing, Sanger sequencing. YH and HYL contributed to sample collection and genetic counselling. All authors read and approved the final manuscript.
Acknowledgements
Gratitude is extended to the subject family for their cooperation and participation.
Due to technical limitations, table 1 is only available as a download in the Supplemental Files section.